Hassan Hassan El-tamimi

PRESENT AFFILIATIONS
Professor of Cardiovascular Medicine, Faculty Lead, Internal Medicine,
Mohammad Bin Rashid University of Medicine and Health Sciences. Dubai, UAE. Head of Cardiology Department,
Mediclinic Parkview Hospital, Dubai, UAE

CITIZENSHIP
United States of America

CURRENT ADDRESS:
Dubai, United Arab Emirates Mobile : +971 56 274 8657
E-mail : heltamimi@hotmail.com

EDUCATION AND CREDENTIALS
Preliminary Education: (1961-1966). St. Nicholas College. Aleppo, Syria.
Secondary Education-Baccalaureate: (1967-1972). The American College in Aleppo. Syria.
BSc: (1973-1976). The American University of Beirut. Beirut, Lebanon. Medical Degree: (1977-82). The American University of Beirut. Beirut, Lebanon
Master’s Degree in Cardiology (MSc): (1984-1986). University of London, Royal Postgraduate Medical School. London, UK.

LICENSURES AND CERTIFICATION
USMLE and ECFMG
Michigan License Registration #4897998 Syrian Ministry of Health Registration #7094 Dubai Health Authority # DHA-P-0045425

POSTGRADUATE TRAINING
Resident in Medicine: (1982–1984)
Chapel Allerton Hospital. University of Leeds. UK.
Registrar in Cardiology: (1984-1985)
Royal Postgraduate Medical School, University of London, Hammersmith Hospital. London, UK.
Sr. Registrar in Cardiology: (1985-1986)
Cardiovascular Unit, Hammersmith Hospital. University of London. UK.
Consultant Cardiologist: (1987-1991)
 
Cardiovascular Unit, Hammersmith Hospital. University of London. UK.

ACADEMIC AND CLINICAL APPOINTMENTS
Senior Lecturer in Cardiology: (1987-1991)
Teaching Fellow
Cardiovascular Unit. Royal Postgraduate Medical School, University of London. UK.
Instructor in Clinical Medicine: (1991-1994)
Senior Clinical Investigator in Cardiology
Division of Cardiology, University of Florida. Gainesville, Florida. USA.
Assistant Professor of Medicine: (1994-1995)
Division of Cardiology, University of Texas Houston. Texas. USA
Associate Professor of Medicine: (1996-1998)
Director, Cardiovascular and Prevention Center
Division of Cardiology. Michigan State University. East Lansing, Michigan. USA.
Professor of Medicine: (1999-2002)
Director, Cardiovascular and Prevention Center
Division of Cardiology. Michigan State University. East Lansing, Michigan. USA.
Director General: (2004-2008)
Consultant Cardiologist
Aleppo University Cardiovascular and Surgical Center. Aleppo University. Syria
Consultant Cardiologist: (2009-2012)
Chairman, Scientific Council
Director, Cardiology Fellowship and Training Program
Al-Bassel Cardiovascular Center, Ministry of Health. Aleppo, Syria.
Consultant Cardiologist; (2014- 2018) Al Zahra Hospital Dubai, UAE
Professor of Cardiovascular Medicine; (2016-Present) Faculty Lead, Internal Medicine.
Mohammad Bin Rashid University of Medicine and Health Sciences. Dubai, UAE
Consultant and Head of Cardiology Department; (2018- Present) Mediclinic Parkview Hospital Dubai, UAE

AWARDS AND HONORS
Distinction and First-Class Honors List: (1975).
The American University of Beirut. Beirut, Lebanon.
“The John Goodwin Award” in recognition of excellence In Cardiology: (1985) The Royal Postgraduate Medical School, Hammersmith Hospital. London, UK. “The Hippocratic Award”. Best Teacher Award (1994)
University of Florida. Gainesville, Florida. USA. “Certificate of Recognition of Excellence” (2006)
During my tenure as a Director General, Aleppo University Cardiac Center.
 
RESEARCH ACTIVITIES
My main interest is clinical research. My research primarily focused on coronary circulation and the role of vascular endothelium in health and disease. It included:
1.    Mechanism of pain in myocardial ischemia.
2.    Coronary vasospasm and manifestation of ischemic syndromes
3.    Effects of calcium antagonists and beta-blockers on coronary circulation
4.    Restenosis after coronary angioplasty.
5.    Coronary hemodynamic and angiographic response to various stimuli.
6.    Vascular biology: role of endothelium in hypertension and hyperlipidemia.
7.    Patterns of care in patients with myocardial infarction and unstable angina.
8.    Hyperlipidemia
9.    Heart Failure
10.    Cardio Kidney Metabolic disorder and obesity
I have conducted several clinical studies testing new and advanced techniques and stents in interventional cardiology. These studies employed stress testing, echocardiography, brachial ultrasound, and coronary angiographic response to various pharmacological interventions (acetylcholine, ergonovine, and nitroglycerin).

MEMBERSHIP OF SCENTIFIC SOCIETIES
Fellow, The Royal Society of Medicine, London Fellow, The New York Academy of Science Fellow, The American College of Cardiology Fellow, The European Society of Cardiology Fellow, The American Heart Association
Founding Member, The Syrian Cardiac Association Member, The American Medical Association
Member, Mohammed bin Rashid Academy of Scientists
 

PUBLISHED ARTICLES IN PEER-REVIEWED JOURNALS

1.    Crea F, El-Tamimi H, Vejar M, Kaski JC, Davies G, Maseri A. Adenosine-induced chest pain in patients with silent and painful myocardial ischemia: another clue to the importance of generalized defective perception of painful stimuli as a cause of silent ischemia. Eur Heart J 1988;9:34-37.
2.    Crea F, Pupita P, Galassi A, El-Tamimi H, Kaski JC, Davies G, Maseri A. A new way to improve exercise capacity with an old drug; theophylline. Lancet 1989; 1:8640-83.
3.    El-Tamimi H, Davies G, Kaski JC, Vejar M, Galassi A, Maseri A. Effects of diltiazem alone or with isosorbide dinitrate or with atenolol both acutely and chronically for stable angina pectoris. Am J Cardiol 1989; 64:717-724.
4.    Hackett D, El-Tamimi H. Holter monitoring after coronary angioplasty. Eur Heart J 1989; 10:33-35.
5.    Crea F, Pupita P, Galassi A, El-Tamimi H, Kaski JC, Davies G, Maseri A. Comparative effects of theophylline and isosorbide dinitrate on exercise capacity in stable angina, and their mechanisms of action. Am J Cardiol 1989;64:1098-1102.
6.    El-Tamimi H, Davies G, Hackett D, Fragasso G, Crea F, Maseri A. Very early prediction of restenosis after successful coronary angioplasty: Anatomical and functional assessment. J Am Coll Cardiol 1990; 15:259-64.
7.    Crea F, Pupita P, Galassi A, El-Tamimi H, Kaski JC, Davies G, Maseri A. Role of adenosine in the pathogenesis of anginal pain. Circulation 1990; 81:164-172.
8.    Newman CM, Maseri A, Hackett DR, El-Tamimi H, Davies GJ. Response of angiographically normal and atherosclerotic left anterior descending coronary arteries to acetylcholine. Am J Cardiol 1990; 66:1070-1076.
 
9.    Crea F, Pupita G, Galassi AR, El-Tamimi H, Kaski JC, Davies G, Maseri A. Effects of theophylline, atenolol, and their combination on myocardial ischaemia in patients with stable angina pectoris. Am J Cardiol 1990; 66:1157-1162.
10.    El-Tamimi H, Davies G, Hackett D, Sritara P, Bertrand O, Crea F, Maseri A. Abnormal vasomotor changes early after coronary angioplasty: a quantitative arteriographic study of their time course. Circulation 1991; 84:1198-1202.
11.    El-Tamimi H, Davies G, Sritara P, Hackett D, Crea F, Maseri A. Inappropriate constriction of small coronary vessels as a possible cause of a positive exercise test soon after successful coronary angioplasty. Circulation 1991; 84:2307-2312.
12.    Tousoulis D, Kaski JC, Davies GJ, Perera W, El-Tamimi H, McFadden E, Maseri A. Pre- angioplasty complicated coronary stenosis morphology as a predictor of restenosis. Am Heart J 1992;123:15-20.
 
13.    El-Tamimi H, Davies G. Optimal control of myocardial ischaemia; the benefit of combination therapy with atenolol and nifedipine. Br Heart J 1992; 68:291.
14.    Pepine CJ, El-Tamimi H, Lambert C. Prinzmetal's Angina (Variant Angina). Heart Disease and Stroke 1992;1: 281-286.
15.    El-Tamimi H, Davies G, Crea F, Maseri A: Response of human coronary arteries to acetylcholine after injury by coronary angioplasty. J Am Coll Cardiol 1993; 21:1152-1157.
16.    Bogaty P, Brecker S, White S, Stevenson R, El-Tamimi H, Balcon R, Maseri A. Different coronary angiographic findings and risk factor profiles in unheralded acute myocardial infarction and uncomplicated chronic stable angina. Circulation 1993; 87:1938-1946.
17.    El-Tamimi H, Mansour M, Wargovich TJ, Hill JA, Kerensky RA, Conti CR, Pepine CJ. Constrictor and dilator responses to intracoronary acetylcholine in adjacent segments of the same coronary artery in patients with coronary artery disease; endothelial function revisited. Circulation 1994; 89:45-51.
18.    El-Tamimi H, Mansour M, Wargovich TJ, Chen H, Mills RM, Nunn C, Pepine CJ. Usefulness of endogenous and exogenous nitric oxide to identify endothelial dysfunction in patients with stable angina pectoris. Am J Cardiol 1994; 74:600-603.
19.    El-Tamimi H, Mansour M, Pepine CJ, Wargovich TJ, Chen H. Circadian variation in coronary tone in patients with stable angina; the protective role of the endothelium. Circulation 1995; 92:3201-3205.
20.    Dwamena FC, El-Tamimi H, Watson RE, Kroll J, Stein AD, McLane A, Holmes-Rovner MM, McIntosh B, Kupersmith J. The use of angiotensin converting enzyme inhibitors in patients with acute myocardial infarction in community hospitals. Clin Cardiol 2000; 23:341-346.

21.    Under-use of beta-blockers following acute myocardial infarction in community hospitals. RE Watson, AB Olomu, FC Dwamena, F Ahmed, P Valilenko, B Mcintosh, H El-Tamimi, JJ Ferlinz. Journal of General Internal Medicine 2002; 17:133-133.
22.    Efficacy and safety assessment of hypertension management with coveram (Perindopril/Amlodipine fixed combination) in patients with previous angiotensin receptor blocker (ARB …M Ahmed, M Alanbaei, H El Tamimi, Y Al-Wahshi, I Al- Zakwani. Current vascular pharmacology 2016; 14(6): 570-575.
23.    Cardiometabolic Guidelines: Cardiovascular Risk Assessment and Management in Patients with Dysglycemia. M Hassanein, H Sabbour, F Al Awadi, S Abusnana, B Afandi, J Al Kaabi, Alaaeldin Bashier, Francesco Cosentino, Hassan El Tamimi, Mohammed Farghali, M Hamed Farooqi, Khadija Hafidh, Hussein Heshmat, Rabih Hijazi, Abdul Jabbar, Sami Kenz, Seema Elkhider Nour, Abdullah Shehab, Jeff Shook, Mohamed Suliman, Hosam Zaky, Wael Almahmeed. Dubai Diabetes and Endocrinology Journal 2023; 29 (2): 67-88.
 
24.    Roadmap for the Management of Type 2 Diabetes and Hypertension in the Middle East: Review of the 2022 EVIDENT Summit. Y Al Saleh, N Al Busaidi, W Al Dahi, M Almajnoni, AS Mohammed, Khalid Alshali, Mostafa Al-Shamiri, Saud Al Sifri, Mohammed Arafah, Siew Pheng Chan, Hassan El-Tamimi, Khadija Hafidh, Mohamed Hassanein, Ashraf Shaaban, Ali Sultan, Guido Grassi. Advances in Therapy 2023; 40 (7): 2965-2984.
25.    Improving Therapeutic Adherence and Reducing Therapeutic Inertia in the Management of People with Cardiometabolic Diseases: A Call-to-Action from the Middle East. W Almahmeed, Z Alabadla, F Al Awadi, D Alrohmaihi, M AlShamiri, Hussein Elbadawi, Hassan El-Tamimi, Abdel-Nasser Elzouki, Mohamed Farghaly, Khadija Hafidh, Mohamed Hassanein, Adel Khalifa Hamad, Kamlesh Khunti, Hani Sabbour, Aletta E Schutte. 2025; Advances in Therapy:1-20.
PUBLISHED ABSTRACTS

1.    Newman C, Hackett D, Fryer M, El-Tamimi H, Davies G, Maseri A. Dual effects of acetylcholine on angiographically normal human coronary arteries in vivo. Circulation 1987;76-IV:238.
2.    Newman C, Hackett D, El-Tamimi H, Maseri A, Davies G. Acetylcholine has dose- dependent bimodal effects on coronary blood flow in man. Medical Research Society 1987. Clin Sci 1988; 74:45.
3.    Newman C, Hackett D, El-Tamimi H, Davies G, Maseri A. Differential effects of acetylcholine on conductance and resistance vessels in patients with angiographically normal coronary arteries. Br Heart J 1988; 59:142.
4.    Vejar M, Galassi A, Kaski JC, El-Tamimi H, Maseri A. Slow release Nifedipine and atenolol for treatment of transient ischemia during daily life. Eur Heart J 1988;9 (suppl 1):201.
5.    Crea F, El-Tamimi H, Vejar M, Galassi AR, Kaski JC, Davies G, Maseri A. Is adenosine responsible for angina pectoris during myocardial ischemia? J Am Coll Cardiol 1988;78(suppl II):4.
6.    Crea F, El-Tamimi H, Vejar M, Galassi A, Kaski JC, Davies G, Maseri A. Is adenosine responsible for angina pectoris during ischemia? Circulation 1988;78: II-422.
7.    El-Tamimi H, Hackett D, Davies G, Larkin S, Maseri A. Can exercise testing predict restenosis after coronary angioplasty? Br Heart J 1989; 61:95.
8.    El-Tamimi H, Davies G, Kaski JC, Vejar M, Maseri A. Acute and chronic effects of diltiazem alone and its combination with atenolol and isosorbide dinitrate. Medical Research Society 1989. Clin Sci 1989;76(suppl 20):15
9.    Crea F, Galassi A, Pupita P, El-Tamimi H, Vejar M, Kaski JC, Davies G. Blockade of adenosine receptors with aminophylline. effects on exercise capacity in stable angina. J Am Coll Cardiol 1989; 12:89.
10.    Crea F, El-Tamimi H, Vejar M, Galassi AR, Kaski JC, Davies G. Adenosine and angina pectoris. Br Heart J 1989;61:5.
11.    Crea F, Pupita G, Galassi AR, El-Tamimi H, Kaski JC, Davies G, Maseri A. The mechanism of anginal pain: possible role of adenosine. Eur Heart J 1989;10 (suppl I):418.
12.    Crea F, Pupita G, Galassi AR, El-Tamimi H, Kaski JC, Davies G, Maseri A. Effect of aminophylline and nitrates on exercise capacity, similar improvement but different mechanism of action. Eur Heart J 1989;10(suppl I):426.
13.    Bonetti F, Fragasso G, El-Tamimi H, Rossetti E, Costantino S, Margonato A, Carandente O, Cherchia S. Duolo del diltiazem e suoi possibili mechanismi d'azione nei pazienti con da sforzo. giornale italiano di CARDIOLOGIA 1989;19(suppl I):170.
 
14.    El-Tamimi H, Davies G, Hackett D, Crea F, Maseri A. Sequential changes in coronary vasoreactivity before and after coronary angioplasty. J Am Coll Cardiol 1990;15(Suppl 2):43
15.    Crea F, Pupita G, Galassi AR, El-Tamimi H, Kaski JC, Davies G, Maseri A. Effects of theophylline, atenolol, and their combination on myocardial ischaemia in patients with stable angina pectoris. Br Heart J 1990;64:56.
16.    El-Tamimi H, Davies G, Hackett D, Crea F, Maseri A. Sequential changes in coronary vasoreactivity before and after coronary angioplasty. Eur Heart J 1990; 11:364.
17.    El-Tamimi H, Davies G, Maseri A. The benefit of fixed combination of atenolol and nifedipine over either drug alone in chronic stable angina. Eur Heart J 1990;11:443.
18.    Kaski JC, Haider AW, Crea F, Tousoulis D, Senior R, El-Tamimi H, Maseri A. coronary stenosis morphology in chronic stable angina with fixed and variable threshold. Eur Heart J 1990; 11:146.
19.    El-Tamimi H, Davies G, Crea F, Hackett D, Maseri A. Acetylcholine causes predominantly distal coronary constriction after coronary angioplasty. Circulation 1990;82: III-617.
20.    El-Tamimi H, Davies G, Hackett D, Crea F, Maseri A. Transient widespread increase in coronary tone soon after coronary angioplasty. Circulation 1990;82: III-617.
21.    El-Tamimi H, Davies G, Agha W. Haidar, Maseri A. Optimal control of myocardial ischaemia; the benefit of combination therapy with atenolol and nifedipine. J Am Coll Cardiol 1991;17(Suppl A):188.
22.    Bogaty P, Brecker S, White S, El-Tamimi H, Stevenson R, Balcon R, Maseri A. Different coronary angiographic findings in unheralded acute myocardial infarction and uncomplicated chronic stable angina. J Am Coll Cardiol 1991;17(Suppl A):254.
23.    El-Tamimi H, Davies G, Crea F, Hackett D, Sritara P, Bertrand O, Maseri A. Reflex vasomotor response of different epicardial coronary artery segments before and after coronary angioplasty. J Am Coll Cardiol 1991;17(Suppl A):300.
24.    El-Tamimi H, Crea F, Davies G, Sritara P, Hackett D, Maseri A. Angiographic and functional assessment one week after coronary angioplasty. Eur Heart J 1991; 12:262.
25.    Bogaty P, Brecker S, White S, El-Tamimi H, Stevenson R, Balcon R, Maseri A. Extent of coronary atherosclerosis is different in unheralded acute myocardial infarction compared with uncomplicated chronic stable angina. Br Heart J 1991; 66:57.
26.    El-Tamimi H, Davies G, Crea F, Sritara P, Hackett D, Maseri A. Dissociation between angiographic and functional assessment of myocardial ischaemia soon after coronary angioplasty. Br Heart J 1991; 66:66.
27.    Tousolis D, Kaski JC, Davies GJ, El-Tamimi H, Crea F, Maseri A. Restenosis after coronary angioplasty: Role of preangioplasty stenosis morphology. Br Heart J 1991; 66:73.
28.    El-Tamimi H, Bertrand M, Maseri A. Lack of magnification of constrictor response by subintimal plaques in patients with chronic stable angina. J Am Coll Cardiol 1992;19(Suppl A):192.
29.    El-Tamimi H, Haider A W, Davies GJ. Optimal control of total ischemic burden; efficacy of atenolol, nifedipine and their combination therapy. Journal of Ambulatory Monitoring 1992;5(Supplement):39.
30.    El-Tamimi H, Mansour M, Wargovich TJ, Hill JA, Mills RM, Nunn C, Kazakis J, Conti J, Pepine CJ. Beta-blockers enhances coronary vasoreactive response to acetylcholine in patients with chronic stable angina. J Am Coll Cardiol 1993;21(Suppl. A):19.
31.    El-Tamimi H, Mansour M, Wargovich TJ, Hill JA, Mills RM, Handberg E, Kazakis J, Nunn C, Azar G, Pepine CJ. Focal hyperreactivity induced by intracoronary acetylcholine in patients with chest pain and normal coronary angiograms: A possible mechanism? J Am Coll Cardiol 1993;21(Suppl. A):476.
32.    El-Tamimi H, Mansour M, Wargovich TJ, Pepine CJ. Lack of association between angiographic lesion severity and the response to intracoronary acetylcholine in stable angina patients with coronary artery disease. Clinical Research 1993;41:117.
 
33.    El-Tamimi H, Mansour M, Wargovich TJ, Hill JA, Kerensky RA, Conti CR, Pepine CJ. Constrictor and dilator responses to intracoronary acetylcholine in adjacent segments of the same coronary artery in patients with coronary artery disease. Clinical Research 1993;41:289.
34.    Wargovich TJ, El-Tamimi H, Mansour M, Pepine CJ. Degrees of coronary endothelial dysfunction does not correspond to severity of obstructive lesion in patients with stable angina. Cathet Cardiovasc Diag 1993;81 A.
35.    El-Tamimi H, Mansour M, Wargovich TJ, Hill JA, Kerensky RA, Mills RM, Chen HJ, Azar GJ, Nunn C, Pepine CJ. Failure of calcium antagonists to prevent acetylcholine induced coronary constriction in patients with stable angina. Eur Heart J 1993; 14:333.
36.    El-Tamimi H, Mansour M, Wargovich TJ, Kerensky RA, Chen HJ, Pepine CJ. Acute beta- blockade enhances coronary vasoactive response to acetylcholine in patients with chronic stable angina. Eur Heart J 1993; 14:299.
37.    El-Tamimi H, Mansour M, Wargovich TJ, Kerensky RA, Chen H, Handberg E, Pepine CJ. Intravenous metoprolol enhances coronary vasoreactive response to acetylcholine in patients with chronic stable angina. Circulation 1993; 88:4-I-493.
38.    El-Tamimi H, Mansour M, Wargovich TJ, Chen H, Hill JA, Kerensky RA, Conti CR, Pepine CJ. Segmental constrictor and dilator responses to intracoronary acetylcholine in patients with coronary artery disease. J Am Coll Cardiol 1994;21(Suppl. A):200.
39.    El-Tamimi H, Mansour M, Wargovich TJ, Chen H, Mills RM, Kerensky RA, Hill JA, Pepine CJ. Use of exogenous and endogenous nitric oxide help identify endothelial dysfunction in patients with stable angina pectoris. J Am Coll Cardiol 1994;21(Suppl. A):200.
40.    Wargovich TJ, El-Tamimi H, Mansour M, Pepine CJ. Do coronary vascular smooth muscle cells become dysfunctional as lesion severity increase? J Am Coll Cardiol 1994;21(Suppl. A):379.
41.    El-Tamimi H, Pepine CJ, Mansour M, Wargovich TJ, Mills R, Chen H. Functional endothelium prevents circadian variation in human coronary tone. Circulation 1994;90:4-I- 294.
42.    El-Tamimi H, Mansour M, Wargovich TJ, Chen HJ, Pepine CJ. Impairment of smooth muscle response to acetylcholine in stenotic coronary segments in patients undergoing coronary angioplasty. Circulation 1994; 90:4-I-392.
43.    El-Tamimi H, Dwamina F, Kroll J, Akhras F, Holmes-Rovner M, Watson R, Kupersmith J. Under-utilization of lipid lowering drugs in patients with CAD in community hospitals. FASEB 1999; 13:4-A86.
44.    Al-Roubaiai H, Neiberg A, Akhras F, El-Tamimi H. Use of cardiac catheterization in patients with unstable angina in community hospitals. FASEB 1999; 13:4-A86.
45.    Al-Roubaiai H, Neiberg A, Holmes-Rovner M, Akhras F, El-Tamimi H. Effects of chest pain severity and ECG changes on the choice of medical intervention in patients with unstable angina in community hospitals. FASEB 1999; 13:4-A86.

BOOK CHAPTERS

1.    El-Tamimi H, Davies G, Al-Yafi F, Fragasso A, Maseri A. Atenolol, nifedipine and their fixed combination in chronic stable angina. In: Descovich GC ed, Atherosclerosis and cardiovascular disease Bologna: Editrici Compositori, 1989.
2.    Pepine CJ, El-Tamimi H, Hill JA, Lambert CR. The patient with known or suspected coronary heart disease: stable ischemic syndromes. In: Pepine CJ ed, Diagnostic and therapeutic cardiac catheterization. Baltimore: Williams and Wilkins, 1994:613-640.
 
INVITED LECTURES (CME, Grand Rounds and International Symposia)

1.    El-Tamimi H. Time course of restenosis following coronary angioplasty assessed by serial exercise testing. "European Society of Cardiology Working Group on Coronary Blood flow and Angina Pectoris" 1988. Namur, Belgium.
2.    El-Tamimi H. Efficacy of atenolol, nifedipine and their fixed combination in patients with stable angina and silent ischemia. "Evolving Concepts in Ischemic Heart Disease". San Francisco, USA, January, 1989.
3.    El-Tamimi H. A comparison of atenolol, nifedipine, and their combination in the treatment of angina pectoris. "7th International Meeting on Atherosclerosis and Cardiovascular disease", Bologna, Italy, September, 1989.
4.    El-Tamimi H. Treatment of chronic stable angina. Is combination therapy better than monotherapy? "The first international workshop on new trends in cardiovascular therapy and technology". June, 1989, Genoa, Italy.
5.    El-Tamimi H. Treatment of chronic stable angina. Is combination therapy better than monotherapy? " XI World Congress of Cardiology". Manila, Philippines 1990.
6.    El-Tamimi H. Early prediction of restenosis after coronary angioplasty: Anatomical and functional assessment. "XI World Congress of Cardiology". Manila, Philippines 1990.
7.    El-Tamimi H. Acetylcholine and vasoreactivity. The American College of Cardiology Extramural Programs. "New Diagnostic and Therapeutic Techniques in Clinical Cardiology". Orlando, Florida, January, 1993.
8.    El-Tamimi H. Coronary endothelial dysfunction before and after angioplasty: detection and implication. The American College of Cardiology Extramural Programs. "Advances in Diagnostic and Therapeutic Cardiac Catheterization". Orlando, Florida, February, 1993.
9.    El-Tamimi H. Heterogeneity of endothelial dysfunction in human coronary arteries; Implications on the genesis of ischemic syndromes. The McIntosh Society, The Watson Clinic, Lakeland, Florida, December, 1993.
10.    El-Tamimi H. Practical aspects of acetylcholine testing in the catheterization laboratory. The American College of Cardiology Extramural Programs. "Advances in Diagnostic and Therapeutic Cardiac Catheterization". Orlando, Florida, February, 1994.
11.    El-Tamimi H. Practical session on intravascular ultrasound. The American College of Cardiology Extramural Programs. "Advances in Diagnostic and Therapeutic Cardiac Catheterization". Orlando, Florida, February, 1994.
12.    El-Tamimi H. Endothelium in Control. The McIntosh Society, The Watson Clinic, Lakeland, Florida, June, 1994.
13.    El-Tamimi H. The role of the endothelium in ischemic syndromes. Cardiac Grand Rounds, Division of Cardiology, Wayne State University, Detroit, Michigan, 1994.
14.    El-Tamimi H. A patient with chest pain, positive exercise test and angiographically normal coronary arteries? Syndrome X. American College of Physicians Scientific Meeting. Houston, Texas, November, 1995.
15.    El-Tamimi H. The role of coronary endothelium in clinical ischemic syndromes. 18th Annual Cardiology Seminar, East Lansing, Michigan, September, 1996.
16.    El-Tamimi H. Management of angina; the importance of the circadian rhythm. Wharton Center, East Lansing, Michigan, February, 1997.
17.    El-Tamimi H. Endothelial dysfunction: The genesis of cardiovascular disease. The American College of Cardiology Satellite Symposium, Anaheim Marriott Hotel, Anaheim, California, March, 1997.
18.    El-Tamimi H. Pathogenesis of atherosclerosis. Calhoun County Medical Society. Battle Creek, Michigan, April, 1997.
19.    El-Tamimi H. Current trends in management of ischemic heart disease. Internal Medicine Grand Rounds, Joliette Hospital, Montreal, Canada. April, 1997.
 
20.    El-Tamimi H. Pathogenesis of atherosclerosis; the role of the endothelium. Cardiology Grand Rounds, Maisonneuve-Rosemont Hospital, University of Montreal, Montreal, Canada. April, 1997.
21.    El-Tamimi H. The role of coronary endothelium in clinical ischemic syndromes. Cardiology Grand Rounds, Royal Victoria Hospital, McGill University, Montreal, Canada. April, 1997.
22.    El-Tamimi H. Atherosclerosis and the vessel wall: From the bench to the bedside. Cardiology Grand Rounds, Montreal Heart Institute, University of Montreal, Montreal, Canada. April, 1997.
23.    El-Tamimi H. The role of the endothelium in coronary artery disease. Cardiology Grand Rounds, Sacre-Coeur de Montreal Hospital, University of Montreal, Montreal, Canada. April, 1997.
24.    El-Tamimi H. The pathogenesis of atherosclerosis and its relationship to clinical ischemic syndromes. The second annual meeting of the Syrian Cardiovascular Association, Latakia, Syria. May, 1997.
25.    El-Tamimi H. Coronary risk factors; the role of the endothelium. Cardiology Grand Rounds, Heart Center for Excellence, Kalamazoo, Michigan. May, 1997.
26.    El-Tamimi H. New advances in lipid therapy. Update-Family practice Lecture Series, Genesys Regional Medical Center, Grand Blanc, Michigan. June, 1997.
27.    El-Tamimi H. The Pathogenesis of atherosclerosis. 19th Annual Cardiology Seminar, East Lansing, Michigan, September, 1997.
28.    El-Tamimi H. Nitric oxide and coronary artery disease. Faculty Seminar, Department of Pharmacology and Toxicology, Michigan State University. Eat Lansing, Michigan, September 1997.
29.    El-Tamimi H. Endothelial dysfunction: The genesis of cardiovascular disease. The Michigan Chapter of the American College of Cardiology. The Ninth Annual Conference. Shanty Creek, Michigan, October, 1997.
30.    El-Tamimi H. The Pathogenesis of myocardial ischemia; the importance of heart rate control. Medicine Grand Rounds. Battle Creek Veterans Affairs Medical Center, Battle Creek, Michigan, November,1997.
31.    El-Tamimi H. Risk Factors and vascular dysfunction in patients with atherosclerosis. Wharton Center, East Lansing, Michigan, November, 1997.
32.    El-Tamimi H. The Pathogenesis of myocardial ischemia; the importance of heart rate control. Sandusky McKensi Memorial Hospital staff meeting, Sandusky, Michigan, December, 1997.
33.    El-Tamimi H. Paradigms for the cardiovascular process; the role of the endothelium in hypertension. Critical Care Grand Rounds, Battle Creek Health System, Battle Creek, Michigan, February, 1998.
34.    El-Tamimi H. The role of the endothelium in hypertension. Update-Family practice Lecture Series, Genesys Regional Medical Center, Grand Blanc, Michigan, 1998.
35.    El-Tamimi H. Hypertension and the vessel wall. Van Buren County Medical Society, South Haven, Michigan. March 1998.
36.    El-Tamimi H. Coronary artery disease and endothelial dysfunction. Medicine Grand Rounds. St. John Hospital and Medical Center. Detroit, Michigan. April, 1998.
37.    El-Tamimi H. Vascular Dysfunction and coronary risk factors. Community Health Center of Branch County. Coldwater, Michigan. April, 1988.
38.    El-Tamimi H. Lipid lowering; A reason for aggressive treatment. WMOA Spring Seminar Muskegon, Michigan. April, 1998.
39.    El-Tamimi, H. Clinical Differentiation of Calcium Channel Blockers. Medicine Grand Rounds. BiCounty Hospital, Warren, Michigan. May, 1998.
40.    El-Tamimi H. Cardiovascular risk factors and vascular dysfunction in patients with atherosclerosis. The third annual meeting of the Syrian Cardiovascular Association, Damascus, Syria. May, 1998.
 
41.    El-Tamimi, H. Hypercholesterolemia: Who to Target, When to Treat, and How to Treat. Kalamazoo Center for Medical Studies, Kalamazoo, Michigan. June, 1998.
42.    El-Tamimi, H. The Calcium Channel Blocker Controversy. Medicine Grand Rounds. Wayne General Hospital, Wayne, New Jersey. June, 1998.
43.    El-Tamimi, H. Key points in risk factors modification. Cardiology Update. Burns Clinic, Petoskey, Michigan. September, 1998.
44.    El-Tamimi, H. Treatment of hypertension; a vascular Approach. Medicine Grand Rounds. Austin Medical Center, Austin, Minneapolis. October, 1998.
45.    El-Tamimi, H. Treatment of hypertension; the role of the endothelium. Medicine Grand Rounds. Lakeland Medical Center, St. Joseph, Michigan. October, 1998.
46.    El-Tamimi, H. Cardiovascular risk factors and vascular dysfunction in patients with atherosclerosis. 20th Annual Cardiology Symposium, East Lansing, Michigan, 1998.
47.    El-Tamimi, H. Treatment of Dyslipidemia. Medicine Grand Rounds. St. Joseph Hospital, Pontiac, Michigan. April, 1999.
48.    El-Tamimi, H. Treatment of hypertension; A Vascular Approach. Medicine Grand Rounds. Northern Michigan Hospital, Petoskey, Michigan. May, 1999.
49.    El-Tamimi, H. Global Approach to risk factors management. Northern Michigan Medical Society Annual Meeting. Grayling, Michigan. May, 1999.
50.    El-Tamimi, H. Aggressive lipid treatment; a clinical imperative. Michigan State University, Department of Medicine Grand Rounds, Sparrow Hospital, East Lansing, Michigan. September, 1999.
51.    El-Tamimi, H. Endothelial Dysfunction and Hypertension. Indiana University, Department of Medicine Grand Rounds, Methodist Hospital, Indianapolis, Indiana. September, 1999.
52.    El-Tamimi, H. Treatment of hypertension; A Vascular Approach. 12th Annual Meeting of the Mediterranean Association of Cardiology and Cardiac Surgery. Damascus, Syria. October, 1999.
53.    El-Tamimi, H. Endothelium, diabetes and cardiovascular disease. 25th Annual Endocrinology and Metabolism Update. Marriott University Place, East Lansing, Michigan. October, 1999.
54.    El-Tamimi, H. Update on the treatment of hypertension. Michigan Osteopathic Association. Shanty Creek, Michigan. January, 2000.
55.    El-Tamimi, H. Aggressive approach to lipid management. Froedtert Hospital Cardiology Grand Rounds, Milwaukee, Wisconsin. March, 2000.
56.    El-Tamimi, H. Hypertension as a vascular disease. Cheboygan Hospital Staff Rounds. Cheboygan, Michigan. July, 20000.
57.    El-Tamimi, H. The role of the endothelium in hypertension. Flower Hospital Medical Grand Rounds. Sylvania, Ohio. September, 2000.
58.    El-Tamimi, H. Assessing coronary artery disease beyond angiography; A focus on vessel wall morphology and function. Al-Bassel Second Meeting in Cardiology and Cardiac Surgery November, 2000. Damascus, Syria.
59.    El-Tamimi, H. The Endothelium as a strategic target for cardiovascular interventions. University of Michigan, Division of Hypertension Grand Rounds, December, 2000. Ann Arbor, Michigan.
60.    El-Tamimi H. The Fifth annual meeting of the Syrian Cardiovascular Association, October 31, 2001. Damascus, Syria.
61.    El-Tamimi H. Evolving insights into coronary artery disease: A new view to managing risk. The First Pan Arab and Sixth Jordanian Internal Medicine Congress, April, 2001. Amman, Jordan.
62.    El-Tamimi H. Emerging therapies in heart failure. The First Pan Arab and Sixth Jordanian Internal Medicine Congress, April, 2001. Amman, Jordan.
63.    El-Tamimi H. Treatment of hypertension: A vascular approach. The First Pan Arab and Sixth Jordanian Internal Medicine Congress, April, 2001. Amman, Jordan.
 
64.    El-Tamimi H. Pathogenesis of atherosclerosis; the role of the endothelium. The Sixth international Conference of the Jordan Cardiac Society, October, 2002. Amman, Jordan.
65.    El-Tamimi H. Treatment of hypertension; the role of the endothelium. The Sixth international Conference of the Jordan Cardiac Society, October, 2002. Amman, Jordan.
66.    El-Tamimi H. New therapies in heart failure. The Sixth international Conference of the Jordan Cardiac Society, October, 2002. Amman, Jordan.
67.    El-Tamimi H. Treatment of hypertension; the role of the Rennin-Angiotensin system. Prince Sultan Military Hospital, Medical Grand Rounds, January, 2003. Riyadh, Saudi Arabia.
68.    El-Tamimi H. The role of the endothelium in health and disease. The American University of Beirut, Cardiology Grand rounds, March, 2003. Beirut, Lebanon.
69.    El-Tamimi H. Treatment of hypertension; the role of the Rennin-Angiotensin system. Hotel Dieu De France, Cardiology Grand rounds, March, 2003. Beirut, Lebanon.
70.    El-Tamimi H. The role of vascular inflammation in hypertension. The General Authority of Health Sciences for the Emirate of Abu Dhabi, Annual Updates in Hypertension Meeting, April 2003. Abu Dhabi, UAE.
71.    El-Tamimi H. Hypertension Updates. The 7th Congress of the Arab Society of Nephrology and Renal Transplantation. February, 2004. Sharm El Sheikh, Egypt.
72.    El-Tamimi H. The Pathogenesis of Atherosclerosis. The 1st Congress of Franco-Syrian Society of Angiology and Vascular Surgery. April, 2004. Damascus, Syria.
73.    El-Tamimi H. Inflammation and cardiovascular disease. The 2nd Pan Arab and 7th Jordanian Internal Medicine Congress, April 2004. Amman, Jordan.
74.    El-Tamimi H. Cell transplantation for cardiac repair. The 2nd Pan Arab and 7th Jordanian Internal Medicine Congress, April 2004. Amman, Jordan.
75.    El-Tamimi H. Effect of beta-blockers in coronary arteries. The 7th Biennial Congress of the Syrian Cardiovascular Association. September 2005. Aleppo, Syria.
76.    El-Tamimi H. Vascular protection in the management of hypertension; role of endothelium. 2nd Middle East Cardiopace. September 2005. Beirut, Lebanon.
77.    El-Tamimi H. Issues in hypertension; which drug and does it matter? Mediterranean Association of Kidney Disease. March 2006. Beirut, Lebanon.
78.    El-Tamimi H. Stabilizing the endothelium. VIIIth International Congress of Cardiology and Cardiac Surgery. April 2007. Beirut, Lebanon.
79.    El-Tamimi H. Stent thrombosis; Clopidogrel, how much and for how long? Middle East Cardiovascular Interventional Conference. Arab Health Congress. 2009. Dubai, UAE.
80.    El-Tamimi H. The role of the endothelium in late stent thrombosis. Turkish Cardiovascular Interventional Association. March 2009. Istanbul, Turkey.
81.    El-Tamimi H. Novel antithrombotic medications. Turkish Cardiovascular Interventional Association. Updates in Interventional Cardiology. October 2011. Istanbul, Turkey.
82.    El-Tamimi H. Vasodilating beta blockers in hypertension. World Heart Federation. April 2012. Dubai, UAE.
83.    El-Tamimi H. Management of Hypertension; Vascular Approach to Hypertension. Bahrain Defense Forces Cardiology Grand Round. April 2015. Bahrain.
84.    El-Tamimi H. Management of Hypertension; An update. Al Zahhra Hospital Dubai Annual Cardiology CME Conference. November 2015. Dubai, UAE.
85.    El-Tamimi H. Acute coronary syndrome; An update. The 25th Ibin Sina Medical CME Conference. Ajman University. April 2015. Ajman, UAE.
86.    El-Tamimi H. Management of hypertension; A vascular view. The 20th Hypertension and Cardiovascular Highlight Sessions. Bahrain Specialist Hospital. March 2016. Bahrain.
87.    El-Tamimi H. Obesity and cardiovascular disease. The 26th Ibin Sina Medical CME Conference. Ajman University. May 2016. Ajman, UAE.
88.    El-Tamimi H. Management of Hypertension; Vascular Approach to Hypertension. Bahrain Defense Forces Cardiology Grand Round. May 2016. Bahrain.
 
89.    El-Tamimi H. A vascular approach to hypertension. The 3rd Qatar Internal Medicine and primary Health Care Conference. October 2016. Doha, Qatar.
90.    El-Tamimi H. Management of dyslipidemia; An update. Al Zahhra Hospital Dubai Annual Cardiology CME Conference. November 2016. Dubai, UAE.
91.    El-Tamimi H. Cardiac Markers. MED LAB Conference. November 2016. Dubai, UAE.
92.    El-Tamimi H. Managing hypertension today; Insight from clinical trials and new guidelines. NCD Integration in Primary health care Workshop. Ministry of Health. January 2017. Dubai, UAE.
93.    El-Tamimi H. New insights in the management of hypertension. European Society of Hypertension Symposium. March 2017. Doha, Qatar.
94.    El-Tamimi H. The Vascular endothelium in health and disease. The Amiri Hospital Cardiology Grand Rounds. April 2017. Kuwait.
95.    El-Tamimi H. Diabetes and heart failure; the cardiologist approach. The 5th Annual gulf medical University Conference on Diabetes and Endocrinology. May 2017. Dubai, UAE.
96.    El-Tamimi H. A vascular prospective to understanding hypertension. Cleveland Clinic Abu Dhabi Medical Grand Round. September 2017. Abu Dhabi, UAE.
97.    El-Tamimi H. A vascular prospective to understanding hypertension. Bahrain cardiology Club Meeting. September 2017. Bahrain.
98.    El-Tamimi H. The vascular endothelium; a new target for treatment of metabolic syndrome. Metabolic syndrome Conference. Health Care Fair. September 2017. Abu Dhabi, UAE.
99.    El-Tamimi H. Updated management of dyslipidemia. Heart Disease Conference. Health Care Fair. September 2017. Abu Dhabi, UAE.
100.    El-Tamimi H. Central blood pressure; Clinical implications. The 21st Hypertension and Cardiovascular Highlight Sessions. Bahrain Specialist Hospital. October 2017. Bahrain.
101.    El-Tamimi H. Addressing the role of nitric oxide in restoring normal endothelial function. The Amiri Hospital Cardiology Grand Rounds. October 2017. Kuwait.
102.    El-Tamimi H. Management of hypertension today; a practical approach to the complex patient. European Society of Hypertension Symposium. November 2017. Dubai, UAE.
103.    El-Tamimi H. How to manage a newly diagnosed NVAF patient undergoing cardioversion? Master Class in Arrhythmia CME Conference. November 2017. Dubai
104.    El-Tamimi H. Practical Use of anticoagulants in atrial fibrillation. Al Zahhra Hospital Dubai Annual Cardiology CME Conference. December 2017. Dubai, UAE.
105.    El-Tamimi H. “Why should cardiologists initiate diabetes treatment for patients with CVD” Emirates Cardiac Society Heart Failure Conference. 23-25 January 2020. Dubai
106.    El-Tamimi H. “Beyond blood pressure reduction; focus on vascular protection” RAAS Fact Checking Symposium, 17 July 2020. Dubai
107.    El-Tamimi H. Hypertension Management; Medical Inertia. Hypertension and Coronary Syndrome Management, 30 September 2020. Dubai
108.    El-Tamimi H. Duration of dual antiplatelet therapy after PCI. Emirates Cardiac Society with European Society of Cardiology, 20-22 October 2020. Dubai
109.    El-Tamimi H. “Should cardiologists initiate diabetes medications” Emirates Diabetes Society, 7-8 November 2020, Dubai
110.    El-Tamimi H. “COVID-19 and cardiac injury” Hypertension Hyperlink Forum, 7, November 2020, Dubai
111.    El-Tamimi H. “Hypertension; A vascular prospective” Advanced Therapy in Hypertension Symposium, 6 December 2020, Dubai
112.    El-Tamimi H. “What do we need to know about latest evidence on SGLT2i in heart failure” In Safe Hands, A Diabetes management Forum, 16 March 2021, Dubai
 
113.    El-Tamimi H. SGLT2i in heart failure, who, when and why?” Heart Failure management Symposium, 31 March 2021, Dubai
114.    El-Tamimi H. “Dapagliflozin in patient with heart failure” Early Action on Heart Failure Treatment, 20 June 2021, Dubai
115.    El-Tamimi H. “cardiovascular disease in type2 DM, How far have we come” Cardiometabolic Academy, 21 June 2021, Dubai
116.    El-Tamimi H. “Prevention in hypertension, hyperlipidemia and diabetes” 11th Annual Hybrid Case Approach to Controversies in CV Disease, 25-26 June 2021, Dubai
117.    El-Tamimi H. Dubai “Targeting non-traditional pathways in heart failure, when and why?” 12th Emirates Cardiac Society with the American Heart Association, 7-9 October, Dubai. Speaker
118.    In Safe Hands, A Diabetes management Forum, 16 March 2021, Dubai “What do we need to know about latest evidence on SGLT2i in heart failure” Speaker
119.    Heart Failure management Symposium, 31 March 2021, Dubai SGLT2i in heart failure, who, when and why?” Speaker
120.    Early Action on Heart Failure Treatment, 20 June 2021, Dubai “Dapagliflozin in patient with heart failure” Speaker
121.    Cardiometabolic Academy, 21 June 2021, Dubai “cardiovascular disease in type2 DM, how far have we come” Speaker
122.    11th Annual Hybrid Case Approach to Controversies in CV Disease, 25-26 June 2021, Dubai “Prevention in hypertension, hyperlipidemia and diabetes” Speaker
123.    12th Emirates Cardiac Society with the American Heart Association, 7-9 October 2022, Dubai “Targeting non-traditional pathways in heart failure, when and why?” Speaker
124.    The Year in Cardiology, Dubai, February 2022. Speaker
125.    Evidence in Diabetes and Hypertension Summit, Jeddah, September 2022. Speaker
126.    Obesity and Cardiology Expert Meeting, Vienna, November 2022. Speaker
127.    Gulf Intervention Society, Dubai, Nov 2022. Speaker
128.    13th Emirates Diabetes and Endocrine Congress, Dubai, February 2023. Speaker
129.    Heart Failure Program, Recent Updates, Dubai, April 23, 2023. Speaker
130.    MBRU Medical Education Symposium, Dubai, October 2023. Speaker
131.    Lipid Symposium, Time to Act, Dubai, October 2023. Speaker
132.    Deep Dive into Dyslipidemia Myths and Realities, Dubai, October 2023. Speaker
133.    Emirates Society of Internal Medicine, Dubai, October 2023. Speaker
134.    Gulf Intervention Society, Dubai, November 2023. Speaker
135.    Mediclinic Abu Dhabi Cardio-Metabolic Summit, Abu Dhabi, November 2023.
136.    The 14th Annual Emirates Cardiac Society, Dubai, November 2023. Speaker